PMID- 35126190
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20220501
IS  - 1664-0640 (Print)
IS  - 1664-0640 (Electronic)
IS  - 1664-0640 (Linking)
VI  - 12
DP  - 2021
TI  - Attenuated Psychotic Symptoms in Adolescents With Chronic Cannabis and MDMA Use.
PG  - 696133
LID - 10.3389/fpsyt.2021.696133 [doi]
LID - 696133
AB  - OBJECTIVES: Both substance use, on the one hand, and the first signs of 
      psychosis, on the other, commonly begin in adolescence. Adolescents with 
      substance use disorder (SUD) frequently show recreational use of cannabis and 
      3,4-methylenedioxymethamphetamine (MDMA). When attenuated psychotic symptoms 
      (APS) occur during the course of SUD, they are commonly attributed to the 
      cannabis use, neglecting the role of other substances abused, such as MDMA in the 
      risk of psychosis. METHODS: We analyzed retrospective self-reports on APS 
      (Prodromal Questionnaire, PQ-16) and amount of cannabis and MDMA use in n = 46 
      adolescent psychiatry outpatients with SUD. N = 17 (35%) individuals reported 
      MDMA consume additional to cannabis. Furthermore, we examined the associations of 
      APS with cannabis and MDMA use in stepwise hierarchical regressions while 
      controlling for trauma history, birth complications and gender. RESULTS: APS were 
      not related to cannabis (B = 0.04, p = 0.842), but to MDMA use (B = 4.88, p = 
      0.001) and trauma history (B = 0.72, p = 0.001). Gender (B = -0.22, p = 0.767) 
      and birth complications (B = -0.68, p = 0.178) were not associated with APS. 
      DISCUSSION: Our results indicate that MDMA use additional to cannabis use is 
      associated with APS among adolescent SUD patients. Contrary to our expectations, 
      we did not see an association of cannabis use and APS. We speculate that cannabis 
      increases the risk for psychosis after a longer period of use and in combination 
      with other risk factors, such as trauma history. Clinicians should screen for APS 
      among SUD patients using MDMA and cannabis in order to adapt treatment plans of 
      SUDs. Future research should validate these findings in longitudinal studies 
      including polysubstance use and trauma history.
CI  - Copyright (c) 2022 Wiedmann, Kuitunen-Paul, Basedow, Roessner and Golub.
FAU - Wiedmann, Melina
AU  - Wiedmann M
AD  - Department of Child and Adolescent Psychiatry, Faculty of Medicine, Technische 
      Universitat Dresden, Dresden, Germany.
FAU - Kuitunen-Paul, Soren
AU  - Kuitunen-Paul S
AD  - Department of Child and Adolescent Psychiatry, Faculty of Medicine, Technische 
      Universitat Dresden, Dresden, Germany.
FAU - Basedow, Lukas A
AU  - Basedow LA
AD  - Department of Child and Adolescent Psychiatry, Faculty of Medicine, Technische 
      Universitat Dresden, Dresden, Germany.
FAU - Roessner, Veit
AU  - Roessner V
AD  - Department of Child and Adolescent Psychiatry, Faculty of Medicine, Technische 
      Universitat Dresden, Dresden, Germany.
FAU - Golub, Yulia
AU  - Golub Y
AD  - Department of Child and Adolescent Psychiatry, Faculty of Medicine, Technische 
      Universitat Dresden, Dresden, Germany.
LA  - eng
PT  - Journal Article
DEP - 20220121
PL  - Switzerland
TA  - Front Psychiatry
JT  - Frontiers in psychiatry
JID - 101545006
PMC - PMC8814345
OTO - NOTNLM
OT  - THC
OT  - addiction
OT  - ecstasy
OT  - marihuana
OT  - psychosis
OT  - substance abuse
COIS- SK-P reports personal fees during the past 36 months from Mabuse Verlag, and a 
      one-time lecture honoraria from a consortium of conference sponsors 
      (Janssen-Cilag, Lilly Germany, Novartis Pharma, Pfizer Pharma). VR has received 
      payment for consulting and writing activities from Lilly, Novartis, and Shire 
      Pharmaceuticals, lecture honoraria from Lilly, Novartis, Shire 
      Pharmaceuticals/Takeda, and Medice Pharma, and support for research from Shire 
      Pharmaceuticals/Takeda and Novartis. He has carried out or is currently carrying 
      out clinical trials in cooperation with the Novartis, Shire 
      Pharmaceuticals/Takeda, Servier and Otsuka companies. The remaining authors 
      declare that the research was conducted in the absence of any commercial or 
      financial relationships that could be construed as a potential conflict of 
      interest.
EDAT- 2022/02/08 06:00
MHDA- 2022/02/08 06:01
PMCR- 2022/01/21
CRDT- 2022/02/07 05:29
PHST- 2021/04/16 00:00 [received]
PHST- 2021/12/13 00:00 [accepted]
PHST- 2022/02/07 05:29 [entrez]
PHST- 2022/02/08 06:00 [pubmed]
PHST- 2022/02/08 06:01 [medline]
PHST- 2022/01/21 00:00 [pmc-release]
AID - 10.3389/fpsyt.2021.696133 [doi]
PST - epublish
SO  - Front Psychiatry. 2022 Jan 21;12:696133. doi: 10.3389/fpsyt.2021.696133. 
      eCollection 2021.